Identification of dihydrofolate reductase in human central-nervous-system tumours.
Ten primary and two metastatic central-nervous system (C.N.S.) tumours were assayed. They all contained dihydrofolate reductase. This finding provides a biochemical rationale for antifolate therapy of C.N.S. tumours by methotrexate.
D000230:Adenocarcinoma / Q000201:enzymology; D001254:Astrocytoma / Q000201:enzymology; D001921:Brain / Q000201:enzymology; D001923:Brain Chemistry; D001932:Brain Neoplasms / Q000188:drug therapy / Q000201:enzymology*; D001943:Breast Neoplasms / Q000201:enzymology; D001984:Bronchial Neoplasms / Q000201:enzymology; D005260:Female; D005909:Glioblastoma / Q000201:enzymology; D005910:Glioma / Q000201:enzymology; D006801:Humans; D008577:Meningeal Neoplasms / Q000201:enzymology; D008579:Meningioma / Q000201:enzymology; D008727:Methotrexate / Q000627:therapeutic use; D009362:Neoplasm Metastasis; D013762:Tetrahydrofolate Dehydrogenase / Q000032:analysis*
D013762:Tetrahydrofolate Dehydrogenase; D008727:Methotrexate